Next week several SeRMN members will present our research work at the Joint Annual meeting ISMRM-ESMRMB 2014 that will take place in Milan (Italy) from 10th to 16th May. Find below a summary of our contributions.
We are recruiting an Early Stage Researcher to work on the Development of Decision Support System & Spectral Classification tool meta-plug-ins for the jMRUI platform as part of the TRANSACT-ITN European project.
We seek a highly motivated and qualified individual as Early Stage Researcher for a three-year applied research project. The successful candidate will contribute to the development of advanced biomedical research tools in the field of Magnetic Resonance Spectroscopy and Imaging, and its application to the clinical day-to-day practice.
The position is intended for a young post-graduate student/researcher, with a Master degree or equivalent on Engineering or Computer Science, and with a proficient knowledge of the Java programming language. Prior experience on signal and/or image processing, segmentation and pattern recognition applications in the field of biomedical research is an asset, particularly in the field of Magnetic Resonance Spectroscopy and/or Imaging.
Transforming Magnetic Resonance Spectroscopy into a Clinical Tool (TRANSACT) is an European research project awarded in the call FP7-PEOPLE-2011-ITN, of the 7th Framework Programme Marie-Curie Actions, to a network of partners including the GABRMN and SeRMN at UAB, and the associated partner CIBER-BBN. The project is coordinated by Prof. Sabine Van Huffel, Prof. Uwe Himmelreich, and Dr. Diana Sima, of the Department of Electrical Engineering ESAT-SCD, and Department of Imaging & Pathology, Biomedical MRI Unit, Katholieke Universiteit Leuven, Leuven, Belgium. Scientist-in-charge at UAB will be Prof. Carles Arús (GABRMN) and Miquel Cabañas (SeRMN), and Dr. Margarida Julià-Sapé will be scientist-in-charge at CIBER-BBN. Dr. Silvia Lope-Piedrafita (SeRMN) will take part in the project as senior scientist.
“Dimethyl sulfoxide (DMSO) as a potential contrast agent for brain tumors”, by Delgado-Goñi T, Martín-Sitjar J, Simões RV, Acosta M, Lope-Piedrafita S, Arús C.; NMR in Biomedicine. 2012.
Identifying the type of brain tumor helps doctors determine the most appropriate course of treatment. Brain tumor diagnosis usually involves a neurological examination, brain scans, and/or an analysis of the brain tissue. Nowadays, the biopsy, although it is a very invasive procedure, is the most accurate method of obtaining a diagnosis. Continue reading DMSO as a magnetic resonance contrast agent for brain tumors
Magnetic resonance spectroscopic imaging (MRSI) of hyperpolarized [1-13C]pyruvate is a promising technique to noninvasively monitor metabolic changes in vivo. This method uses dynamic nuclear polarization (DNP) techniques to obtain tens of thousands fold enhancement in the polarization of [1-13C]pyruvate and its metabolic products, like lactate, providing sufficient MR signal for high spatial and temporal resolution spectroscopic imaging of these metabolites. Continue reading Hyperpolarized 13C magnetic resonance metabolic imaging in a mouse brain glioma model